GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (NAS:BPMC) » Definitions » 10-Year ROIIC %

BPMC (Blueprint Medicines) 10-Year ROIIC % : -121.20% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Blueprint Medicines's 10-Year ROIIC % for the quarter that ended in Dec. 2023 was -121.20%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Blueprint Medicines's 10-Year ROIIC % or its related term are showing as below:

BPMC's 10-Year ROIIC % is ranked worse than
67.45% of 1275 companies
in the Biotechnology industry
Industry Median: -33.25 vs BPMC: -121.20

Blueprint Medicines 10-Year ROIIC % Historical Data

The historical data trend for Blueprint Medicines's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines 10-Year ROIIC % Chart

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -121.20

Blueprint Medicines Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -121.20 - - -

Competitive Comparison of Blueprint Medicines's 10-Year ROIIC %

For the Biotechnology subindustry, Blueprint Medicines's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's 10-Year ROIIC % falls into.



Blueprint Medicines 10-Year ROIIC % Calculation

Blueprint Medicines's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -482.9368399 (Dec. 2023) - -21 (Dec. 2013) )/( 383.977 (Dec. 2023) - 2.838 (Dec. 2013) )
=-461.9368399/381.139
=-121.20%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Blueprint Medicines  (NAS:BPMC) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Blueprint Medicines 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Executives
Kate Haviland officer: Chief Business Officer BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Christina Rossi officer: Chief Commercial Officer 45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139
Lonnel Coats director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Jeffrey W. Albers director, officer: CEO & President BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Fouad Namouni officer: President, R and D 535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116
Michael Landsittel officer: Principal FAO BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Philina Lee officer: Chief Commercial Officer C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Debra Durso-bumpus officer: Chief People Officer C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Percy H. Carter officer: Chief Scientific Officer C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
L. Becker Hewes officer: Chief Medical Officer C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139
Ariel Hurley officer: Principal Accounting Officer C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Christopher K. Murray officer: SVP, Technical Operations C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Tracey L Mccain officer: EVP and Chief Legal Officer C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
John Tsai director BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139

Blueprint Medicines Headlines

From GuruFocus